Ovid Therapeutics Inc. Income Statement
OVID|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Ovid Therapeutics Inc. reported $566,000 in revenue and $26M in net loss for FY2025. Revenue has declined at a 86.0% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $566.0K | $392.0K | $1.5M | $208.4M |
| SG&A Expense | $25.7M | $31.1M | $32.4M | $37.2M |
| R&D Expense | $36.8M | $28.6M | $24.6M | $46.9M |
| Operating Income | -$61.9M | -$59.3M | -$55.5M | $124.2M |
| Income Tax | $0 | $0 | $0 | $1.3M |
| Net Income | -$26.4M | -$52.3M | -$54.2M | $122.8M |
| EPS (Basic) | - | - | -$0.77 | $1.78 |
| EPS (Diluted) | - | - | -$0.77 | $1.76 |
| Shares Outstanding | 71.0M | 70.7M | 70.5M | 70.4M |
| Operating Margin | -10933.8% | -15122.7% | -3696.4% | 59.6% |
| Profit Margin | -4670.1% | -13351.8% | -3604.7% | 59.0% |